A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors

Inclusion Criteria

• •1. Locally advanced or metastatic solid tumors who meet 1 of the following 4 criteria:
• •* With locally advanced or metastatic ALK-positive NSCLC who have progressed on or are intolerant to treatment with at least 1 other ALK inhibitor.
• •* With ALK-positive nonlung solid tumors that are locally advanced or metastatic and for whom no standard, nonexperimental therapy is available.
• •* With locally advanced or metastatic ROS1-positive NSCLC who have progressed on crizotinib therapy or are intolerant to crizotinib, or
• •* With ROS1-positive nonlung solid tumors that are locally advanced or metastatic and for whom no standard, nonexperimental therapy is available.
• •2. Eastern cooperative Oncology Group (ECOG) performance status of 0 or 1.
• •3. Have at least 1 target lesion per response evaluation criteria in solid tumors (RECIST) version 1.1.
• •4. Have recovered from toxicities related to prior anticancer therapy to National Cancer Institute common terminology criteria for adverse events (NCI CTCAE) version 4.03 Grade less than or equal to (\<=) 1.
• •5. Suitable venous access for study-required blood sampling (that is, including PK and laboratory safety tests).